ALLSTAR Phase I/II
The ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial is a Phase I/II trial evaluating the safety and efficacy of the CAP-1002 therapeutic candidate– Capricor’s allogeneic, off-the-shelf, cardiosphere-derived cell product candidate. The trial is being sponsored by Capricor, and Drs. Timothy Henry and Rajendra Makkar of the Cedars-Sinai Heart Institute are the principal investigators. The trial is being conducted at approximately 30 sites across the U.S and in Canada.
The Phase I portion of the trial was funded in part by the National Institutes of Health and completed enrollment in December 2013, and the Phase II portion of the trial is supported in large part with the support of the California Institute for Regenerative Medicine (CIRM).
Please visit ClinicalTrials.gov (NCT01458405) for more information regarding the ongoing ALLSTAR Phase I/II clinical trial.